A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Although this patient had none of these common risk factors associated with Candida empyema, she did have other factors predisposing her to fungal colonization and subsequent infection.
Investigators designed a quasi-experimental pre- and post-intervention analysis comparing a pre-intervention cohort receiving IV drip antibiotic infusion with a post-intervention cohort receiving IVP administration.
Unique challenges can affect the success of the shift from pediatric to adult care settings.
A multidisciplinary panel concludes a discussion on best practices for managing patients with HIV in various healthcare settings and overcoming social health disparities.
The latest article from SIDP offers a Top 5 list of how to precept a learner on an infectious disease rotation.
There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.
Those with certain comorbidities, including peptic ulcer disease and renal failure, were at additional risk of developing C diff infection.
Here are some insights into this upcoming 2021-2022 influenza season as well as concerns of the twindemic and addressing both the seasonal and pandemic viruses simultaneously.
With the population of adults with HIV growing older, incorporating age-based screenings, comprehensive assessments, and morbidity management into routine HIV care is essential in improving health outcomes and quality of life.
The management of hospital-acquired pneumonia requires use of preventive bundles, mitigative of risk factors, and prompt diagnosis with initiation of treatment when highly suspected.
Access to antifungal susceptibility testing (AFST) remains limited in the United States. Therefore, providers must recognize clinical situations where AFST will provide its greatest value. In the latest article from SIDP, infectious disease pharmacists offers some insights on this subject.
Nonspecific, nondolent symptoms make this disease difficult to diagnose.
Outside of vaccines, these underutilized therapies are the best defense against severe disease.
Introducing “Bench to Bedside With SIDP,” a new column covering everything from antimicrobial stewardship and pharmacokinetics/pharmacodynamics to mentorship, preceptorship, and more.
Similar to HIV, the colonial and postcolonial history is fundamental to the biology of this monkeypox outbreak.
In the latest column from SIDP, the authors discuss having leaders to help navigate school and beyond.
Due to worsening headaches and unrevealing cross-sectional imaging and ascites fluid analyses, this patient's differential evolved toward a central nervous system source.
In the latest column from SIDP, clinicians discuss that along with the once-daily dosing for many indications, there are also compelling indications for twice-daily dosing.
A balance between antimicrobial stewardship and the search for multidrug-resistant organisms.
The Centers for Disease Control and Prevention (CDC) reports the rise in pediatric acute respiratory illnesses especially as there is a decrease in hygiene measures that were previously employed during the pandemic.
Closing out their discussion on Clostridioides difficile infection, panelists share closing thoughts on novel pipeline therapies.
Joseph Eron, MD, Daniel R. Kuritzkes, MD, and Monica Gandhi, MD, MPH, discuss the likelihood of other combination regimens for the treatment of multidrug-resistant HIV, including monoclonal antibodies.
At 7.1%, vitamin C deficiency in the US is rare. Unfortunately, identifying scurvy is complex, frustrating, and time-consuming for both patient and provider.
As the number of COVID-19 cases continues to rise, oral treatment options for at-home use are in demand to provide early intervention and reduce the progression to severe disease, hospitalization, and death.
Vaccinations and mitigations for COVID-19 and other respiratory viruses have not been made a priority for young children. Let’s change this before the next big surge hits.
This novel therapeutic option represents the first long-acting injectable approved for maintenance of HIV-1 suppression.